CCTG Director Dr. Janet Dancey, elected to Canadian Academy of Health Sciences

The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.

Dr. Dancey is an international leader in cancer clinical trials of experimental therapeutics and has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology, including development of novel trials for patients with rare tumours. As Director, she has advanced CCTG’s research strategy and expanded its portfolio dramatically. A prolific author with an excellent citation record, she is a sought-after speaker, both nationally and internationally.

In addition to being CCTG Director, Dr. Dancey is the Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN) and was Director of the High Impact Clinical Trials Program at the Ontario Institute for Cancer Research. Prior to joining CCTG, she was Senior Clinical Investigator in the Cancer Therapy Evaluation Program at the US National Cancer Institute and then Associate Chief of the Investigational Drug Branch.

The CAHS elects individuals who have demonstrated leadership and creativity throughout their careers and have been recognized by their peers for their contributions to the promotion of health sciences. As a member of the CAHS, Dr. Dancey will spend the next three years providing analysis on, and solutions to, Canada’s most complex health concerns.